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Letter Regarding Article by Tsimikas et al,
“High-Dose Atorvastatin Reduces Total Plasma
Levels of Oxidized Phospholipids and Immune
Complexes Present on Apolipoprotein B-100 in
Patients With Acute Coronary Syndromes in the
MIRACL Trial”
To the Editor:
Tsimikas et al hypothesized that in the MIRACL (Myocardial
Ischemia Reduction with Aggressive Cholesterol Lowering)
study statins induced a net efflux of oxidized phospholipids
(OxPL) from the vessel wall, which is reflected by an increased
OxPL/apoB ratio, representing enrichment in OxPL of apoB
particles.1 We would like to suggest an alternative interpretation.
The oxidized low-density lipoprotein (OxLDL)-E06 assay used
captures apoB-containing particles from the plasma sample.
Because plasma lipoprotein(a) (Lp(a)) increased and LDL de-
creased during statin treatment, more Lp(a) and fewer LDL
particles were captured after statin treatment. Because OxPL are
predominantly associated with Lp(a),2 the increased OxPL/apoB
ratio could be explained by the shift in the Lp(a)/LDL ratio.
Similarly, in the placebo-treated group the decreased OxPL/apoB
ratio results from a decrease in Lp(a) relative to LDL. It is
therefore unlikely that the OxPL/apoB ratio is a surrogate marker
of net removal of OxPL from the vessel wall. Moreover, the
observed 30% decrease in total plasma apoB-OxPL also argues
against an increased net efflux of OxPL from the vessel wall.
Recently, using the OxLDL assay from Mercodia in which an
oxidation epitope associated with apoB is detected with mono-
clonal antibody 4E6, we found that atorvastatin (80 mg/d) and
simvastatin (40 mg/d) reduced total plasma Ox-apoB (43% and
35%, respectively) in patients with familial hypercholesterol-
emia from the ASAP study.3 Interestingly, we observed no
change in the Ox-apoB/apoB ratio when we used the noncom-
petitive version of the kit, in which the immobilized antibody
captures Ox-apoB from the sample. We did, however, observe a
small increase in the Ox-apoB/apoB ratio (18% for atorvastatin,
13% for simvastatin) when we used the competitive version,
which unlike the noncompetitive version is sensitive to the
number of oxidation epitopes associated with apoB. In addition,
the increase in Ox-apoB/apoB ratio can be explained by an
increase in Lp(a) relative to LDL. To further address this
question, measurements of OxLDL with E06 and 4E6 in well-
designed assays (eg, in isolated Lp(a) particles) at different time
points after the start of statin treatment are required.
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We thank Van Tits et al for their interesting analysis of our
data.1 Although we cannot absolutely rule out that their
interpretation is correct, we strongly favor our interpretation
for the following reasons: (1) 4E6 binds malondialdehyde-
lysine epitopes on LDL, which have not been documented to
be present on Lp(a) per se, and does not bind the OxPL that
are recognized by E06 and present on Lp(a). Thus, the
increase in their “oxidized apoB/apoB” ratio cannot be ex-
plained by increased Lp(a) levels. (2) Similar increases in
OxPL/apoB and Lp(a) were noted in response to low-fat diets2
and immediately after angioplasty,3 in which only 50% of the
OxPL were physically present on Lp(a), whereas the rest were
on non-Lp(a) apoB-containing lipoproteins, conditions under
which one may postulate efflux of OxPL from the vessel wall.
(3) As pointed out in the Discussion in our original article, our
hypothesis is strongly supported by unpublished studies in
animals, including rabbits that do not have Lp(a), showing
similar increases in OxPL/apoB with concomitant decreases in
total OxPL-apoB and reduced vessel wall immunostaining for
OxPL in response to regression diets. Therefore, the increased
OxPL/apoB that accompanies lesion regression is clearly not
the result of changes in Lp(a). We have additional evidence in
humans that Lp(a) is the preferential (but not obligatory)
acceptor of OxPL, which explains the strong association with
Lp(a).4
Unlike the OxPL/apoB measure, the Mercodia OxLDL assay
strongly correlated with LDL (r0.70) in multiple studies and
may not be independent of LDL. The methodology for the
competition assay is not described and therefore we are unable to
assess whether the parameters the authors describe are indepen-
dent of apoB.
Comparative studies of current OxLDL assays are needed to
understand their clinical utility. We agree that a focus of ongoing
research should be to test the hypothesis that Lp(a) binding of
OxPL is an innate immune mechanism to clear proinflammatory
OxPL, and in particular to understand the mechanisms respon-
sible for the increase in Lp(a) levels in response to statins or
low-fat diets.
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